



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |  |
|--|--|--|--|
| (51) International Patent Classification <sup>6</sup> :<br>C07K 14/705, C12N 15/62 // C07K 19/00   |  | A1   | (11) International Publication Number: WO 98/42750             |
|  |  |  | (43) International Publication Date: 1 October 1998 (01.10.98) |
| (21) International Application Number: PCT/SE98/00555  |  | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |  |
| (22) International Filing Date: 26 March 1998 (26.03.98)   |  |  |  |
| (30) Priority Data:<br>9701127-4 26 March 1997 (26.03.97) SE   |  |  |  |
| (71) Applicant (for all designated States except US): KAROLIN-SKA INNOVATIONS AB [SE/SE]; S-171 77 Stockholm (SE).   |  |  |  |
| (72) Inventors; and<br>(75) Inventors/Applicants (for US only): HOLGERSSON, Jan [SE/SE]; Venusvägen 6A, S-141 33 Huddinge (SE). LIU, Jining [CN/SE]; Röntgenvägen 1, S-141 52 Huddinge (SE). |  | Published<br>With international search report.   |  |
| (74) Agents: KILANDER, Annika et al.; Albihns Patentbyrå Stockholm AB, P.O. Box 3137, S-103 62 Stockholm (SE).   |  |  |  |

(54) Title: ANTIGENIC FUSIONPROTEIN CARRYING GAL $\alpha$ 1,3GAL EPTOPES

(57) Abstract

The present invention relates to an antigenic fusionprotein, which carries multiple Gal $\alpha$ 1,3Gal epitopes. The fusion protein according to the invention may also be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1, and a part, which exhibits immunoglobulin properties, such as the Fc part of IgG. The fusionprotein according to the invention is preferably used as an absorber to prevent a hyperacute rejection of a xenotransplant, such as a pig tissue or organ transplanted into a human patient. In addition, the invention relates to a method for the prevention of a hyperacute rejection reaction in a patient who is to receive a xenotransplant.



B

